- Home
- Most Recent Content
Most Recent Content
TIO 2023 – Atrioventricular Valve Replacement Beyond TEER? – Live Cases & Discussions
- 1.00
Published:
Learning objectives
- Compare the utility of repair and replacement valve technology in mitral regurgitation
- Individualise valve choice for aortic regurgitation based on valve durability and patient features
- Recall the utility and limitations of specialty balloons
- Evaluate emerging approaches to the treatment of complex left main and other coronary bifurcation lesions
- Discuss the impact of PCI on top of optimal medical therapy in ischaemic left ventricular systolic dysfunction
- Identify suitable patients for interatrial shunting
- Discuss the merits of alternative antiplatelet strategies to DAPT in ACS and CCS following PCI
TIO 2023 – Atrioventricular Valve Replacement Beyond TEER?
- 1.00
Published:
Learning objectives
- Compare the utility of repair and replacement valve technology in mitral regurgitation
- Individualise valve choice for aortic regurgitation based on valve durability and patient features
- Recall the utility and limitations of specialty balloons
- Evaluate emerging approaches to the treatment of complex left main and other coronary bifurcation lesions
- Discuss the impact of PCI on top of optimal medical therapy in ischaemic left ventricular systolic dysfunction
- Identify suitable patients for interatrial shunting
- Discuss the merits of alternative antiplatelet strategies to DAPT in ACS and CCS following PCI
Hyperkalaemia in Cardiorenal Disease – A Case Based Discussion
- Not accredited
Published:
Learning objectives
- Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
- Identify patients who would benefit from anti-hyperkalaemia medications
- Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
- Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
- Summarise current guideline recommendations on the use of potassium binding agents
Examining a Complex Heart Failure Case
- 1.00
Published:
Learning objectives
- Identify individuals likely to have HFpEF from initial presentation
- Refer suspected individuals for specialist assessment
- Initiate GDMT for HF as soon as patients are stable
- Initiate GDMT in HF regardless of EF and phenotype
- Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists
CVD and Type 2 Diabetes: Navigating Therapeutic Boundaries in GLP-1 RA Use
- 2.00
Published:
Learning objectives
- Describe the burden of ASCVD in type 2 diabetes
- Assign risk of future CV events to individuals with type 2 diabetes
- Identify appropriate patients for GLP-1 RA therapy based on clinical trial outcome data to reduce ASCVD risk
- Recall trial data of anti-diabetes medications that reduce ASCVD risk
- Recall the pleiotropic effects of GLP-1 RAs and how these may impact CV outcomes
- Describe how early adoption of anti-diabetes therapies with proven CV benefit can positively influence QOL
- Adopt anti-diabetic therapies with proven ASCVD benefit
Individualising Antithrombotic Strategies for Established CAD
- 1.00
Published:
Learning objectives
- Summarise current guidance for choosing antithrombotic therapy in established CAD
- Describe current gaps in clinical evidence and what is missing from current guidance
- Adopt an evidence-based approach for managing patients with ACS and CCS
Obstructive Hypertrophic Cardiomyopathy: Getting It Right First Time
- 1.00
Published:
Learning objectives
- Recall the general approach to diagnosis and stratification of HCM according to the latest guidelines and expert opinion
- Apply advanced echocardiographic methodologies to equivocal HCM diagnoses
- Select appropriate imaging modalities to facilitate accurate risk stratification
- Stratify patients based on specific risk features and disease severity
- Choose suitable treatment modalities for patients based on specific disease features and severity
Incorporating GDMT and PRO Endpoints for Personalised HF Management
- 1.00
Published:
Learning objectives
- Review current GDMT in HFrEF and HFpEF
- Describe the relationship between initiation of GDMT and HF outcomes
- Prescribe GDMT according to current international recommendations
- Recall the elements of the Kansas City Cardiomyopathy Questionnaire
- Describe the clinical studies that support the use of functional and QoL measures in practice
- Initiate quality of life and functional improvement measures in routine practice
- Initiate SGLT-2 inhibitors in patients presenting with De novo HF and in patients already on other GDMT
- Adopt shared decision-making with HF patients
Transcatheter Edge-to-Edge Repair: An Assessment of its Long-term Impact on Mitral Regurgitation
- 1.00
Published:
Learning objectives
- Recall the long-term outcomes of TEER from real-world and RCT data
- Apply the results of real-world data to both simple and complex patients
- Describe how TEER is being used to benefit a range of patients with MR